The Hu Lab at Stanford has developed a neuroprotective gene therapy for treating glaucoma and other optic neuropathies. Their gene therapy AAV vector expresses NMNAT2 operably linked to a retinal ganglion cell-specific promoter (mSngc).
Researchers at Stanford have developed a methodology for deep learning-based image reconstruction by incorporating the physics or geometry priors of the imaging system with deep neural networks.
SparseGMM, is a new algorithm which is a novel statistical approach for identifying drug targets in cancer patients and other diseases by more accurately modeling biological pathways.
Stanford researchers have developed a novel approach to make a stable and active platinum-alumina catalyst that maintains high activity under harsh conditions.
Stanford researchers have developed a new controllable methodology for molecularly targeted ultrasound contrast agent production with pre-formed ligand-phospholipid bioconjugates.
Stanford researchers have developed an integrated printer/scanner platform to screen biofluids for bacterial pathogens and other cells of interest at the single cell level.
Researchers led by Stanford University's Stephen Tsai have developed new design and manufacturing approaches for glueless/boltless joining of metallic grid and carbon composite skins.
Stanford researchers have designed a new 3-dimensional (3D) hydrogel cell culture system that models native tissue environment with precise control over gelation and degradation properties.
Stanford scientists in Dr. Paul Wender's lab have developed a novel method to synthesize tigilanol tiglate (EBC-46) and related compounds from readily available starting materials.
Researchers at Stanford have developed synthetic transcription elongation factors (Syn-TEFs) to treat proliferative diseases, including repeat expansion mutations in cancer.
The Follmer group has designed a soft jamming brake and artificial muscle (SJBAM) actuator for improved muscle static and dynamic response along with expanded brake bandwidth.
Researchers in Prof. Matthew Scott's laboratory have discovered that small-molecule inhibitors of casein kinase II (CK2) could be used as a targeted therapy for pediatric medulloblastoma or other Shh/hedgehog-related tumors.